Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (IPHA) news covers the company’s progress as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. As a dual-listed issuer on Euronext Paris (IPH) and Nasdaq (IPHA), Innate Pharma regularly publishes regulatory and corporate updates that are relevant to investors following immuno-oncology and antibody-based therapeutics.
News about Innate Pharma frequently highlights developments across its antibody-engineering and ANKET® (Antibody-based NK cell Engager Therapeutics) platform. Company releases describe clinical and regulatory milestones for key assets such as IPH4502, a differentiated Nectin-4 ADC in solid tumors; lacutamab, a first-in-class anti-KIR3DL2 monoclonal antibody in cutaneous and peripheral T cell lymphomas; and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Investors can expect updates on clinical trial progress, including Phase 1, Phase 2 and Phase 3 studies, regulatory designations for pipeline assets, and collaboration news involving partners such as Sanofi and AstraZeneca. Innate Pharma’s news flow also includes financial communications, such as business updates, financial results, financial calendars, and regulatory disclosures on the number of shares outstanding and voting rights under French market rules.
This news page aggregates these company communications in one place, making it easier to follow Innate Pharma’s clinical pipeline evolution, partnership activities and key corporate events. Readers interested in immuno-oncology, antibody-drug conjugates, NK cell engagers and collaboration-driven biotech models can use this feed to monitor how Innate Pharma reports its progress over time.
Innate Pharma announced that the European Medicines Agency (EMA) has granted PRIME designation to lacutamab, its first-in-class anti-KIR3DL2 antibody, for treating patients with relapsed or refractory Sézary syndrome. This designation is based on positive efficacy and safety data from ongoing clinical trials, including the Phase 1 and Phase 2 TELLOMAK study. Lacutamab is designed to target unmet medical needs in cutaneous T-cell lymphoma patients, showing promise for those who have undergone multiple previous therapies.
Innate Pharma announced participation in several virtual investor conferences. Key events include the Bryan Garnier Conference on November 17, the Jefferies Conference on November 18, and the SVB Leerink Oncology Day on November 19, 2020. The Evercore ISI HealthCONx is scheduled for December 1-3, 2020, with a fireside chat on December 2. Presentations will be available for replay on the company's website. Innate Pharma focuses on innovative oncology treatments, notably Lumoxiti, approved for hairy cell leukemia, and has partnerships with major biopharmaceutical firms.
Innate Pharma announced the launch of HopeConnectLearn, a new online resource for the hairy cell leukemia community. This platform aims to provide education and connection for patients and caregivers, covering the disease from diagnosis to relapse. Hairy cell leukemia accounts for 2-3% of adult leukemia cases in the U.S., with around 1,000 new diagnoses annually. The initiative seeks to empower patients with information, fostering community support.
Innate Pharma SA (Nasdaq: IPHA) announced that AstraZeneca has dosed the first patient in the Phase 3 clinical trial, INTERLINK-1, evaluating monalizumab with cetuximab for R/M SCCHN patients previously treated with platinum-based therapies. This milestone triggers a $50 million payment from AstraZeneca, enhancing Innate's cash position through 2022. The trial aims to investigate overall survival among approximately 600 patients. Prior studies indicated a response rate of 20-27.5% for the combination, highlighting an unmet medical need in this patient demographic.
On October 1, 2020, Innate Pharma announced its total number of shares outstanding and voting rights, complying with French regulations. The company has 78,981,290 ordinary shares and additional 6,921 and 7,581 preferred shares from 2016 and 2017, respectively. Total theoretical voting rights stand at 79,799,621, with 79,781,046 exercisable voting rights. Innate Pharma, focused on oncology and immunotherapy, aims to enhance cancer treatment through its innovative antibody pipeline, including Lumoxiti, approved by the FDA.
Innate Pharma reported significant progress in its clinical pipeline, resuming enrollment in the Phase 2 lacutamab study for Sézary syndrome and mycosis fungoides. The Phase 3 study for monalizumab, partnered with AstraZeneca, is set to trigger a $50 million milestone payment upon initiation. The company holds a cash position of €184.6 million as of June 30, 2020, despite a decrease in revenue to €36.7 million from €59.2 million in the prior year. Operating expenses slightly increased to €46 million, and a net loss of €10.3 million was reported, compared to a net income of €13.2 million in H1 2019.
Innate Pharma (Euronext: IPH, Nasdaq: IPHA) will participate in three upcoming virtual investor conferences in September 2020. These include the Citi’s 15th Annual BioPharma Virtual Conference from September 08-11, Goldman Sachs 10th Annual Biotech Symposium on September 11, and the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16. The company focuses on oncology treatments using therapeutic antibodies. Its key product, Lumoxiti, is approved for hairy cell leukemia and represents a significant advancement in cancer therapy.
Innate Pharma has secured €6.8M funding under the PSPC-COVID initiative to advance its COVID-19 research efforts. This funding from Bpifrance, a French government investment bank, aims to support R&D, including Phase II clinical trials initiated in March 2020. The funding will be disbursed in four tranches, with the first being €1.7M. The Company is focusing on its COVID-19 programs, such as the FORCE trial, which targets severe pneumonia in COVID-19 patients, and the ImmunONCOVID-20 study, which explores treatments for cancer patients with COVID-19 symptoms.